CA2751215A1 - Cell lines expressing cftr and methods of using them - Google Patents

Cell lines expressing cftr and methods of using them Download PDF

Info

Publication number
CA2751215A1
CA2751215A1 CA2751215A CA2751215A CA2751215A1 CA 2751215 A1 CA2751215 A1 CA 2751215A1 CA 2751215 A CA2751215 A CA 2751215A CA 2751215 A CA2751215 A CA 2751215A CA 2751215 A1 CA2751215 A1 CA 2751215A1
Authority
CA
Canada
Prior art keywords
cftr
cell
cells
intron
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2751215A
Other languages
English (en)
French (fr)
Inventor
Kambiz Shekdar
Jessica Langer
Srinivasan P. Venkatachalan
Dennis J. Sawchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of CA2751215A1 publication Critical patent/CA2751215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049Channel-conductance-controlling ATPase (3.6.3.49)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/38Pediatrics
    • G01N2800/382Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2751215A 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them Abandoned CA2751215A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14931209P 2009-02-02 2009-02-02
US61/149,312 2009-02-02
PCT/US2010/022778 WO2010088630A2 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Publications (1)

Publication Number Publication Date
CA2751215A1 true CA2751215A1 (en) 2010-08-05

Family

ID=42396394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2751215A Abandoned CA2751215A1 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Country Status (6)

Country Link
US (2) US20120058918A1 (enExample)
EP (1) EP2393930A4 (enExample)
JP (1) JP2012516686A (enExample)
CA (1) CA2751215A1 (enExample)
MX (1) MX2011008131A (enExample)
WO (1) WO2010088630A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2245046B1 (en) * 2008-01-22 2019-09-04 Chromocell Corporation Novel cell lines expressing nav and methods using them
CA2713885A1 (en) * 2008-02-01 2009-08-20 Chromocell Corporation Novel cell lines and methods
WO2011014740A2 (en) 2009-07-31 2011-02-03 Chromocell Corporation Methods and composition for identifying and validating modulators of cell fate
WO2012162468A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Thiazol derivatives as pro -matrix metalloproteinase inhibitors
US20130014288A1 (en) * 2011-06-06 2013-01-10 Carnegie Mellon University Novel reporter-tagged recombinant membrane proteins with transmembrane linkers
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
WO2017196843A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN111910008B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种鸡生长发育相关的分子标记及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) * 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing
WO2004020596A2 (en) * 2002-08-30 2004-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Polypeptides for increasing mutant cftr channel activity
AU2005251745A1 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2602793C (en) * 2005-04-13 2016-11-22 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
MX2008014437A (es) * 2006-05-19 2008-11-27 Scripps Research Inst Tratamiento de desplegamiento de proteinas.
WO2008121199A2 (en) * 2007-03-28 2008-10-09 University Of Iowa Research Foundation Transgenic animal models of disease

Also Published As

Publication number Publication date
EP2393930A4 (en) 2012-08-15
MX2011008131A (es) 2012-01-20
EP2393930A2 (en) 2011-12-14
US20120058918A1 (en) 2012-03-08
WO2010088630A3 (en) 2010-11-25
US20150315554A1 (en) 2015-11-05
JP2012516686A (ja) 2012-07-26
WO2010088630A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
US20150315554A1 (en) Cell lines expressing cftr and methods of using them
EP2391647B1 (en) Cell lines expressing nav and methods of using them
CN101960014B (zh) 细胞系以及制备和使用其的方法
Boeckers et al. C‐terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3
EP2622351B1 (en) Neuropeptide q as modulator of gpcr galr2 and uses thereof
Wang et al. Functional evaluation of a novel GRIN2B missense variant associated with epilepsy and intellectual disability
Du et al. Functional characterization of novel NPRL3 mutations identified in three families with focal epilepsy
US20120028278A1 (en) Cell lines expressing guanylate cyclase-c and methods of using them
WO2007089591A2 (en) Compositions and methods for high throughput screening of pharmacological chaperones
Kadhim et al. Transcriptional coactivator MED15 is required for beta cell maturation
Yoshinaga et al. Dysregulation of N-terminal acetylation causes cardiac arrhythmia and cardiomyopathy
Pastore et al. Autism-Associated PTCHD1 Missense Variants Bind to the SNARE-Associated Protein SNAPIN but Exhibit Impaired Subcellular Trafficking
Lv et al. Regulation of Hedgehog Signaling Through Arih2-Mediated Smoothened Ubiquitination and Endoplasmic Reticulum-Associated Degradation
Shaikh Control of cellular trafficking of mammalian voltage sensitive phosphatase (VSP) through protein-protein interactions
Plach Serotonin 5-HT2A-Dopamine D2 Receptor Heterodimers: Characterization and Functional Evaluation
HK1152321B (en) Cell lines expressing gabaa and methods of using them
Powlowski Exploring Voltage-Gated Sodium Channel NaV1. 6 as an Interacting Partner with G Protein-Coupled Receptors
Silva Identifying the effects of mutations in the Rab domain on Leucine-Rich Repeat Kinase 2 (LRRK2) function
HK1167875A (en) Novel cell lines and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150130

FZDE Discontinued

Effective date: 20200121